Efficacy of rh‑PDGF‑BB and Emdogain With or Without DFDBA Using M-MIST in the Treatment of Intrabony Defects

Abstract

Background: The versatile combination of emdogain or enamel matrix derivative (EMD), recombinant human platelet-derived growth factor-BB (rhPDGF-BB), and  demineralized freeze-dried bone allograft (DFDBA) has not been utilized in the treatment of intrabony defects yet.

Aim: The present study attempted to  investigate the efficacy of a combination of simple, uncomplicated nature of modified minimally invasive surgical technique (M‑MIST) with EMD, rhPDGF- BB, and DFDBA in the surgical management of intrabony defects and to assess the possible favorable effects for a period of 6 months.

Patients and  Methods: Thirty healthy subjects were included in the present double-blind, randomized controlled, two-arm parallel study. The test group was treated  with M-MIST by using rhPDGF-BB, EMD, and DFDBA, and the control group was treated with M-MIST by using rhPDGF-BB and EMD.

Results: Differences  between the mean values of primary clinical parameters including relative attachment level, probing depth, and gingival recession at baseline and those  at 6 months after surgery were statistically significant in both groups. Inter-group comparison for clinical attachment level gain, probing depth reduction,  and change in the position of gingival margin revealed no statistically significant differences. Inter‑group comparison revealed significant  differences in linear bone growth (LBG) and percentage bone fill (% BF) but no significant differences in the residual defect depth and change in the  alveolar crest position.

Conclusion: The additional use of DFDBA provides superior benefits in terms of LBG and % BF in intrabony defects. This  improvement might be attributed to the use of an osteoinductive scaffold.